ArticleFrontiers in psychiatry2026
Association between the triglyceride-glucose index and the risk of post-stroke depression.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-stroke depression (PSD) is a common complication after stroke that affects prognosis. The triglyceride-glucose (TyG) index, a surrogate marker of insulin resistance, is associated with cerebrovascular diseases, but its relationship with PSD remains unclear. This study investigated the association between TyG index and PSD risk in first-ever acute ischemic stroke (AIS) patients. Methods: We enrolled 398 consecutive first-ever AIS patients and calculated baseline TyG index. PSD was assessed using the 17-item Hamilton Depression Rating Scale at 3 months post-stroke. Logistic regression, restricted cubic splines (RCS), and threshold effect models were used to evaluate the association and dose-response relationship. Results: At 3 months, 126 patients (31.66%) developed PSD. The PSD group had significantly higher TyG index than the non-PSD group (9.03[8.34-9.34] vs. 8.56[8.17-9.05], P < 0.001). After adjusting for sex, NIHSS score, LDL-C, and HDL-C, TyG index remained independently associated with PSD (OR = 1.64, 95% CI: 1.28-2.09, P < 0.001). Patients in the highest TyG quartile had a significantly increased PSD risk compared with the lowest quartile (OR = 3.40, 95% CI:1.73-6.68, P < 0.001). RCS analysis revealed a non-linear relationship, with a turning point at 8.02 identified by threshold effect analysis; above this value, PSD risk increased significantly (OR = 1.97, 95% CI:1.43-2.72, P < 0.001). Subgroup analyses showed significant interactions in patients with diabetes (P for interaction = 0.046) and hyperlipidemia (P for interaction = 0.026). Conclusions: Elevated TyG index is independently associated with increased PSD risk in a non-linear manner. A TyG index ≥ 8.02 may serve as a risk threshold for PSD, and this association appears more pronounced in patients with diabetes or hyperlipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.